BlueWhale Bio is advancing a technology platform intended to accelerate and lower the cost of cell and gene therapy manufacturing. The company emerged from the Danaher Ventures Pioneer Program and was spun out of the University of Pennsylvania. Its science team is led by immunotherapy pioneers Carl June and James Riley, who serve as consultants and hold equity in the company. The University of Pennsylvania has granted BlueWhale Bio an option to enter into a license for certain Penn intellectual property. Led by CEO Peter Keller, the company plans to use new capital to expand operations and its R&D sector. The article reports a recent capital raise of $18M to support these plans.

Total raised

$18M

Funding rounds

1

Latest round

Seed

Latest activity

Sep 2023